Who are probenecid 250 Milligrams (mg)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): urate oxidase, Benzbromarone (drug), phenytoin and probenecid, ULO, olmesartan medoxomil+probenecid, Bempedoic Acid Tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/probenecid-250-milligrams-mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

probenecid 250 Milligrams (mg) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

probenecid 250 Milligrams (mg) (probenecid 250 Milligrams (mg)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: uricosuric. Area: Rheumatology.

phase 3 uricosuric Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

probenecid 250 Milligrams (mg) (probenecid 250 Milligrams (mg)) — University of Miami. Probenecid works by inhibiting the reabsorption of uric acid in the kidneys, thereby increasing its excretion in the urine.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
probenecid 250 Milligrams (mg) TARGET	probenecid 250 Milligrams (mg)	University of Miami	phase 3	uricosuric
urate oxidase	urate oxidase	Sanofi	marketed	Uricosuric enzyme	Uric acid
Benzbromarone (drug)	Benzbromarone (drug)	Tottori University Hospital	marketed	Uricosuric agent	URAT1 (urate transporter 1)
phenytoin and probenecid	phenytoin and probenecid	Jim McAuley	marketed	Anticonvulsant and uricosuric agent combination	Voltage-gated sodium channels (phenytoin); organic acid transporter (probenecid)
ULO	ULO	Merck Sharp & Dohme LLC	marketed	Uricosuric agent; URAT1 inhibitor	URAT1 (urate transporter 1)
olmesartan medoxomil+probenecid	olmesartan medoxomil+probenecid	Central South University	marketed	Angiotensin II receptor blocker + uricosuric agent	AT1 receptor (angiotensin II type 1 receptor); uric acid transporter (URAT1)
Bempedoic Acid Tablet	Bempedoic Acid Tablet	Gan & Lee Pharmaceuticals.	phase 3	Uricosuric agent / Xanthine oxidase inhibitor	AMPK (AMP-activated protein kinase) / Xanthine oxidase pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (uricosuric class)

University of Miami · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). probenecid 250 Milligrams (mg) — Competitive Intelligence Brief. https://druglandscape.com/ci/probenecid-250-milligrams-mg. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing